Why Isn’t Ivermectin Being Widely Researched and Utilized?

Why Isn’t Ivermectin Being Widely Researched and Utilized

On November 13, a scientific review manuscript was posted to OSF, a medical pre-print server by Pierre Kory, MD, of the Front Line COVID-19 Critical Care Alliance (FLCCC). On November 3, TrialSite reported on the inclusion of the drug in the Alliance’s I-MASK+ protocol; the new manuscript comprehensively reviews the entirety of the emerging evidence from recent publications in journals, pre-print servers, and randomized trial results posted on clinicaltrials.gov. The FLCCC was created in March by Professor Paul Marik, MD, in order to continuously analyze the quickly-evolving science and clinical data for the purpose of creating COVID-19 treatment protocols. The corresponding author for the review is Pierre Kory, MD, MPA, an Associate Professor of Medicine at St. Luke’s Aurora Medical Center. 

While Other Drugs Have Failed, Ivermectin Studies are Now Showing Consistent and Substantial Benefits

The Alliance writes that, to date, much of the research being conducted and the care being given has been plagued by the use of medicines at, “inappropriate time points during this now well-described multi-phase disease.” And at this point, due to either trial design errors or lack of e...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee